- Home
- TLSI
as 01-17-2025 4:00pm EST
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | WESTMINSTER |
| Market Cap: | 150.3M | IPO Year: | N/A |
| Target Price: | $11.75 | AVG Volume (30 days): | 33.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.50 - $10.42 | Next Earning Date: | 11-14-2024 |
| Revenue: | $26,891,000 | Revenue Growth: | 67.90% |
| Revenue Growth (this year): | 60.96% | Revenue Growth (next year): | 53.65% |
Latest TriSalus Life Sciences Inc. News
TLSI Breaking Stock News: Dive into TLSI Ticker-Specific Updates for Smart Investing
TipRanks
9 days ago
TriSalus Life Sciences announces publication of pre-clinical data
Business Wire
10 days ago
TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System
Business Wire
11 days ago
TriSalus Announces Leadership Changes
Argus Research
a month ago
Daily – Vickers Top Insider Picks for 12/10/2024
Argus Research
a month ago
Daily – Vickers Top Insider Picks for 12/09/2024
Argus Research
a month ago
Daily – Vickers Top Insider Picks for 12/06/2024
Argus Research
a month ago
Daily – Vickers Top Insider Picks for 12/05/2024
Argus Research
a month ago
Daily – Vickers Top Insider Picks for 12/04/2024
Compare TLSI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TLSI TriSalus Life Sciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.